卡司替凡联合卡博替尼治疗既往接受过治疗的透明细胞肾细胞癌患者：ARC-20 扩展队列研究结果 (NCT05536141).pdf

1、Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma:results from an expansion cohort of ARC-20(NCT05536141)Toni K Choueiri,MD,FASCO1;Moshe Ornstein,MD,MA2;Pedro Barata,MD,FACP3;Marc Matrana,MD,FACP4;JamieMerchan,MD5;Craig Gedye,MBChB,FRACP,PhD

2、6;Clara Hwang,MD7;Rohit Kumar,MD8;Jae LyunLee,MD,PhD9;Yinghui Guan,MS,PhD10;Mohammad Ghasemi,PhD10;Syed Quadri,MD10;Chris Negro,MS10;Jianfen Chen,MS10;Paul Foster,PhD10;Deepti Warad,MBBS10;Bradley A McGregor,MD1;Sun Young Rha,MD,PhD11;Alexandra Drakaki,MD,PhD121Dana Farber Cancer Institute,Boston,MA

3、,USA;2Cleveland Clinic,Cleveland,OH,USA;3University Hospitals Seidman Cancer Center,Cleveland,OH,USA;4Oschsner Health,New Orleans,LA,USA;5Department of Medical Oncology,University of Miami Leonard M.Miller School of Medicine,University of Miami,Miami,FL,USA;6ICON Cancer Centre Adelaide,Kurralta Park

4、,SA,Australia;7Henry Ford CancerDetroit,Detroit,MI,USA;8James Graham Brown Cancer Center,University of Louisville,Louisville,KY,USA;9Asan Medical Center,University of Ulsan College of Medicine,Seoul,South Korea;10Arcus Biosciences,Inc.,Hayward,CA,USA;11Yonsei Cancer Center,Yonsei University College

5、of Medicine,Seoul,South Korea;12Division of Hematology/Oncology,David Geffen School of Medicine,University of California Los Angeles,Los Angeles,CA,USAHIF-2 Is a Key Driver in the Development and Progression of ccRCC1 Hypoxic response EPO/red blood cell generationCell Growth/CycleAngiogenesis&Oxygen

6、 SupplyEpithelial-MesenchymalTransitionMetastasisMetabolism Cholesterol uptake Fatty acids Lipoproteins Migration/invasion Extracellular matrix/cell-cell interaction Cytoskeleton organization Stemness Proliferation DNA repair Ribosome biogenesis E2F/MYC targetsHIF-2HIF-1HundredsofGenesUpregulated1.C